Neurizon

This webinar was EPIC…

Still time to register for this exclusive Fierce Biotech event and learn about the latest breakthroughs in the ALS development with Neurizon and Ncardia.

We look forward to connecting with industry leaders and experts, and sharing the latest discoveries in the Neuroscience field at #BioNeuroscience conference next week. If you are attending, please reach out to Dr Michael Thurn and Sergio Duchini who will be representing Neurizon and discussing our latest progress in bringing NUZ-001 forward as a potential ALS/MND therapy to patients.

Walking Together for the ALS/MND Community 💙 This weekend, the Neurizon Therapeutics team proudly joined the MND Relay, walking side by side with patients, families, and advocates in the fight against motor neurone disease (MND/ALS). More than just a race, this event symbolizes endurance, resilience, and hope—values that drive our mission every day. As a company dedicated to advancing innovative treatments for ALS, we are committed not only behind the scenes but also in the community. We’ve volunteered, raised funds, and taken meaningful steps—both on the track and in our work—to bring new possibilities to patients who need them most. To everyone fighting this battle, we walk with you. And to the incredible MND Relay community and MND Victoria, thank you for inspiring us to push forward. #MND #ALS #HorizonOfHope #NeurizonTherapeutics #NeurodegenerativeDiseases #MakeItMatter #MNDRelay

A recent paper published in Nature Aging by Dr. Sabrina Paganoni and colleagues underscores the groundbreaking impact of the HEALEY ALS Platform Trial—a game-changing approach that accelerates discoveries and improves trial efficiency. This innovative model has the potential to revolutionize how we bring new treatments to patients with MND/ALS faster. At Neurizon Therapeutics, we are honored to be part of this pioneering effort as we prepare to evaluate NUZ-001 in this Trial. We believe this collaboration brings us another step closer to offering new hope to patients and their families. #ALSResearch #HEALEYALSTrial #NeurizonTherapeutics #HorizonOfHope #NeurodegenerativeDiseases

We look forward to joining Ncardia for an exclusive Fierce Biotech webinar about the latest in ALS research and drug development. Join us on Feb 20th at 1 PM ET and hear from the global leaders Dr. Michael Thurn and Jeroen De Groot who are driving the innovation in this field. Register at https://lnkd.in/eXQW9CVp #ALS #MND #NeurodegenerativeDiseases #innovation #NeurizonTherapeutics #Ncardia

Our CEO, Dr. Michael Thurn, recently spoke with Sean Boss about the significance of our newly granted U.S. patent for NUZ-001, reinforcing our position in the fight against neurodegenerative diseases, and in particular ALS/MND. This is a crucial step forward in our mission to bring transformative therapies to patients in need. Watch the full interview here: https://lnkd.in/gkc6BUsD

We are thrilled to announce that the United States Patent and Trademark Office (USPTO) has granted a patent covering the use of our lead drug candidate, NUZ-001, in neurodegenerative diseases, such as ALS/MND.   🔹 Extends IP protection in the U.S. until 2039 for NUZ-001 and related compounds targeting mTOR pathway-related diseases 🔹 Strengthens commercial potential and lays a solid foundation for future commercial discussions 🔹 Follows FDA Orphan Drug Designation (ODD) granted in May 2024, further reinforcing our IP estate and market position   This milestone propels our mission forward as we advance NUZ-001’s clinical development for ALS/MND and other neurodegenerative diseases.   Read the full press release at: https://lnkd.in/e3cSKCpi

Join Neurizon Therapeutics & Ncardia for an Exclusive live Webinar, "Breaking New Ground in ALS Research", on February 20 at 1:00 PM ET." This session will explore the latest breakthroughs in ALS drug development, including: ✅ NUZ-001’s potential as an innovative MND/ALS therapy—leveraging mTOR inhibition to reduce TDP-43 protein aggregation, a key pathological feature of ALS. ✅ How Ncardia’s cutting-edge iPSC-based platforms are transforming preclinical research and accelerating drug discovery. At Neurizon Therapeutics, we are committed to advancing innovative therapies for MND/ALS and ensuring patients have access to the treatments they need. Don't miss this opportunity to gain valuable insights into the future of ALS research. 🔗 Register now at: https://lnkd.in/ggy-dRdq

We are excited to share our latest Quarterly Activities Report and Appendix 4C, highlighting key advancements in our mission to develop innovative therapies for neurodegenerative diseases. 💡 NUZ-001 continues to show promise as a potential innovative therapy for ALS: ✅ Preclinical data reinforce its ability to reduce TDP-43 protein aggregation, a key pathological feature of ALS. ✅ 8-month interim results from the OLE study remain encouraging, further supporting NUZ-001’s potential. ✅ Regulatory progress continues as we work to bring this therapy to those who need it most. Each milestone brings us closer to a future where patients with ALS have more treatment options. Thank you for your continued support as we drive innovation forward! 🔗 Read the full update here: https://lnkd.in/em8EPkHh